Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7186 to 7200 of 8904 results

  1. Gastroelectrical stimulation for gastroparesis (IPG103)

    Interventional procedures, IPG103 - Issued: December 2004 --> This guidance has been updated and replaced by NICE interventional procedure guidance 489.

    Withdrawn guidance

  2. Impedance-controlled endometrial ablation for menorrhagia (IPG104)

    Summary --> This guidance has been updated and replaced by NICE guideline CG44.

    Withdrawn guidance

  3. Coil embolisation of unruptured intracranial aneurysms (IPG105)

    We have moved interventional procedures guidance 105 to become HealthTech guidance 63. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Laser in situ keratomileusis (LASIK) for the treatment of refractive errors (IPG102)

    This guidance has been replaced by NICE interventional procedure guidance 164.

    Withdrawn guidance

  5. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  6. The EOS 2D/3D imaging system (DG1)

    We have moved Diagnostics guidance 1 to become HealthTech guidance 274. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)

    This guidance has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn guidance

  8. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    We have moved Diagnostics guidance 14 to become HealthTech guidance 353. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)

    This guidance has been updated and replaced by NICE HealthTech guidance 552.

    Withdrawn guidance

  10. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    We have moved Diagnostics guidance 16 to become HealthTech guidance 360. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    We have moved Diagnostics guidance 13 to become HealthTech guidance 348. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

    We have moved Diagnostics guidance 19 to become HealthTech guidance 388. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

    We have moved Diagnostics guidance 18 to become HealthTech guidance 386. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)

    This guideline has been updated and replaced by NICE guideline NG131.

    Withdrawn guidance

  15. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)

    Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.

    Withdrawn guidance